Treatment of Symptomatic Gastrointestinal Motility Disturbances in Systemic Sclerosis
Gastrointestinal involvement is a recognised feature of systemic sclerosis. When patients develop symptomatic motility disturbances of the GI tract in the context of SSc, specific pharmacological management is indicated.
Clinical scenario
This protocol applies to patients with systemic sclerosis who present with symptomatic gastrointestinal motility disturbances — a complication that requires targeted treatment to address GI dysfunction in this population.
Treatment approach
Current evidence supports a pharmacological approach using a specific class of agents directed at improving GI motility. The full regimen — including agent selection, sequencing, and clinical considerations — is detailed in the structured protocol.
References
The use of prokinetic drugs should be considered for the treatment of symptomatic motility disturbances related to SSc.
DOI: 10.1136/ard-2024-226430
View source ↗